Piramal Enterprises Ltd (PEL) is looking at growing organically in pharmaceutical segment to move up the value chain and expanding in services like antibody drug conjugates, injectables and drug discovery.  

In the last two years, the pharma segment deployed around half a billion dollar of capital for future growth through various organic as well as inorganic initiatives.

PEL is now looking at investments for expansion of the manufacturing and service delivering capabilities in niche areas of ADC, injectables, inhalation anaesthesia and discovery services.

It also plans to launch first generic version of Desflurane, the latest generation inhalation anaesthesia product, in FY18.

Last year, the company added two niche differentiated product portfolios in global pharma products business.

It has acquired a portfolio of five branded products in the injectable anaesthesia and pain management area from Janssen and a portfolio of intrathecal spasticity and two pain management products under development from Mallinckrodt LLC.

The company has strengthened its presence in North America and Europe - and generates over 70 percent of its revenues from these two geographies, which host close to 70 percent of its assets.